Skip to Content

Alessandra Ferrajoli

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1988 School of Medicine, University of Perugia, Perugia, Italy, MD, Cum Laude, Medicine

Board Certifications

12/2012 American Board of Medical Oncology
1/2008 American Board of Internal Medicine

Experience/Service

Institutional Committee Activities

Member, Clinical Research Committee, 9/2011-present
Member, ICU Subcommittee, 9/2011-present
Member, Credentials Committee of the Medical Staff (CCMS), 9/2010-8/2013
Vice-Chair, M. D. Anderson Clinical Effectiveness Committee, 9/2007-present
Member, M. D. Anderson Internal Review Board, 9/2005-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Coombs CC, Falchi L, Weinberg JB, Ferrajoli A, Lanasa MC. Chronic lymphocytic leukemia in African Americans. Leuk Lymphoma 53(11):2326-9, 11/2012. e-Pub 7/2012. PMID: 22646816.
2. Ferrajoli A. Interfering with CD40 Ligation: A Sensitive Matter in Chronic Lymphocytic Leukemia. Leuk Lymphoma 53(11):2093-2094, 11/2012. e-Pub 5/2012. PMID: 22563816.
3. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 9/15/2012. e-Pub 1/26/2012. PMID: 22282348.
4. Coombs CC, Rassenti LZ, Falchi L, Slager SL, Strom SS, Ferrajoli A, Weinberg JB, Kipps TJ, Lanasa MC. Single-nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood 120(8):1687-90, 8/2012. e-Pub 6/2012. PMCID: PMC3429309.
5. Garg R, Wierda W, Ferrajoli A, Abruzzo L, Pierce S, Lerner S, Keating M, O'Brien S. The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer 118(14):3531-3537, 7/2012. e-Pub 12/2011. PMID: 22139735.
6. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 119(20):4614-8, 5/2012. e-Pub 3/2012. PMID: 22422826.
7. Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 53(3):417-423, 3/2012. e-Pub 11/2011. PMID: 21879809.
8. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol 42(12):1989-2000, 12/2011. e-Pub 7/2011. PMID: 21733558.
9. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-Positive acute lymphoblastic leukemia cells. Invest New Drugs 29(6):1206-1212, 12/2011. e-Pub 6/2010. PMID: 20533075.
10. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. J Clin Oncol 29(31):4088-95, 11/2011. e-Pub 10/2011. PMID: 21969505.
11. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118(13):3489-3498, 9/2011. e-Pub 7/2011. PMID: 21725050.
12. Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117(17):3999-4008, 9/2011. e-Pub 2/2011. PMID: 21858802.
13. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-2093, 8/2011. e-Pub 6/2011. PMID: 21670470.
14. Ferrajoli A, Keating MJ, O'Brien S, Cortes J, Thomas DA. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer 117(14):3182-3186, 7/2011. e-Pub 1/2011. PMID: 21246526.
15. Ferrajoli A, Buzdar AU, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. Cancer 117(14):3268-3275, 7/2011. e-Pub 1/2011. PMID: 21264831.
16. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-3024, 3/2011. e-Pub 1/2011. PMID: 21245487.
17. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-3024, 2011.
18. Motta M, Wierda WG, Ferrajoli A. Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer 115(17):3830-3841, 2009. e-Pub 6/2009. PMID: 19536902.
19. Ferrajoli A. Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 50(3):514-516, 2009. PMID: 19347738.
20. Ferrajoli A, Lee B-L, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11):5291-5297, 2008. PMID: 18334676.
21. Ferrajoli A, Wierda WG, Lapushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Eur J Haematol 80(4):296-298, 2008. PMID: 18182081.
22. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myeloid leukemia cells. Cancer Res 67(23):11291-11299, 2007. PMID: 18056455.
23. Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 6(8):671-679, 2006. PMID: 17168672.
Other Articles
1. Ferrajoli A, O'Brien SM, Faderl S, Wierda WG, Reuben JM, Keating MJ. Lenalidomide: An emerging option in chronic lymphocytic leukemia. Haematologica Meeting Reports 3(3):103-105, 2009.

Grant & Contract Support

Title: Phase II Study of Ofatumumab as Front-line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL)
Funding Source: NCCN - National Comprehensive Cancer Network
Role: Principal Investigator
Duration: 10/10/2011 - 10/9/2015

Last updated: 6/20/2013